{
  "CitationSubset": [],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "19300081",
  "DateCompleted": {
    "Year": "2009",
    "Month": "07",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2009",
    "Month": "03",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1097/CNQ.0b013e3181a27ffb"
    ],
    "Journal": {
      "ISSN": "1550-5111",
      "JournalIssue": {
        "Volume": "32",
        "Issue": "2",
        "PubDate": {
          "Year": "2009",
          "Season": "Apr-Jun"
        }
      },
      "Title": "Critical care nursing quarterly",
      "ISOAbbreviation": "Crit Care Nurs Q"
    },
    "ArticleTitle": "Interferon and heart disease.",
    "Pagination": {
      "StartPage": "159",
      "EndPage": "162",
      "MedlinePgn": "159-62"
    },
    "Abstract": {
      "AbstractText": [
        "Heart disease is the leading cause of morbidity and mortality in the United States. Atherosclerosis is the major cause of heart disease. It is a chronic inflammatory response. Many factors contribute to this chronic inflammation. This review looks at the role of interferon gamma in atherosclerosis."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Nursing and Health Studies, Georgetown University, Washington, DC 20057, USA. angerioa@georgetown.edu"
          }
        ],
        "LastName": "Angerio",
        "ForeName": "Allan D",
        "Initials": "AD"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Crit Care Nurs Q",
    "NlmUniqueID": "8704517",
    "ISSNLinking": "0887-9303"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
    },
    {
      "RegistryNumber": "82115-62-6",
      "NameOfSubstance": "Interferon-gamma"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "complications",
        "immunology",
        "prevention & control"
      ],
      "DescriptorName": "Atherosclerosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Causality"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chronic Disease"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Diet, Fat-Restricted"
    },
    {
      "QualifierName": [
        "epidemiology",
        "etiology",
        "prevention & control"
      ],
      "DescriptorName": "Heart Diseases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Inflammation"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "immunology"
      ],
      "DescriptorName": "Interferon-gamma"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Morbidity"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "United States"
    }
  ],
  "NumberOfReferences": "38"
}